Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235625 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL7539678 | 0.91 | CRBN (0.42) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL1810703 | 0.83 | PARP1 (0.37) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL15701568 | 0.79 | CHRM2 (0.45) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL3422044 | 0.77 | LMNA (0.37) | OPRM1OPRD1OPRK1OGFRL1LMNA | |
| SCHEMBL19370610 | 0.77 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL30997780 | 0.76 | CRBN (0.38) | CRBNALDH1A1MAPT | |
| SCHEMBL1814278 | 0.75 | CALCRL (0.37) | OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL840638 | 0.74 | CRBN (0.33) | OPRM1OPRD1OPRK1OGFRL1CRBN | |
| SCHEMBL31436228 | 0.72 | MAPT (0.44) | OPRM1OPRD1OPRK1OGFRL1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601291-B1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12162886-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3860714-B1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-110831945-B | 11, 13-modified saxitoxins for the treatment of pain | 赛特温治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-111868060-B | Dihydropyridino phthalazinone derivatives, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20220259218-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-08-18 | — | — | US | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-1371687-A | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2002-10-02 | — | — | CN | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| CN-1253775-A | Refractory vasculitis therapeutic preparation | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-05-24 | — | — | CN | disclosed |
| CN-1159324-A | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | CN | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | OPRM1 270/4885OPRD1 174/4885OPRK1 192/4885 |
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | OPRM1 4362/4885OPRD1 4391/4885OPRK1 3414/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | OPRM1 270/4885OPRD1 174/4885OPRK1 192/4885 |
| US-20220259218-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | OPRM1 270/4885OPRD1 174/4885OPRK1 192/4885 |
| US-12162886-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, SCN3A | OPRM1 177/4885OPRD1 146/4885OPRK1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.